Antonija Sakic | Chief Business and Corporate Development Officer
Antion Biosciences SA

Antonija Sakic, PhD in biomedical sciences, is the Chief Business and Corporate Development Officer at Antion Biosciences, where she leads strategy, partnerships, licensing, fundraising, and investor and stakeholder engagement. In this role, she directs the advancement of the company’s proprietary miRNA-based gene modulation platform, miRGE™, which enables efficient, tunable, and multiplex gene silencing while addressing key challenges of gene editing approaches such as off-target effects, immunogenicity, and improving safety, scalability, and physiological relevance. Antonija drives collaborations and strategic initiatives that support the company’s growth in the rapidly expanding CGT market.